In this issue:
No benefit to the addition of cetuximab to chemotherapy in CUP
Risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy
Most oncology therapies are approved without demonstrating QoL benefit
Remote online symptom monitoring system (eRAPID) beneficial for cancer patients
Adjuvant chemotherapy superior to chemoradiation in resectable gastric cancer
Nivolumab, paclitaxel and ramucirumab for refractory gastric cancer
Early interdisciplinary supportive care extends survival in esophagogastric cancer
Tumour-specific fluorescence-guided surgery for liver metastases
Dose-reduced gemcitabine plus nab-paclitaxel for elderly patients with PAC
Modified frailty index not appropriate for use in advanced PAC
Please login below to download this issue (PDF)